Suja Life priced its initial public offering at $21 per share on Wednesday, selling 8.9 million shares and raising $186.9 million before underwriting fees. The San Diego-based cold-pressed juice and functional beverage company began trading on Nasdaq under ticker SUJA, marking the first significant consumer packaged goods debut in fourteen months.

The pricing came at the midpoint of the company's filed range. Suja Life had registered to sell shares between $19 and $23, and underwriters chose the center. No pop, no discount. The company now carries a fully diluted market capitalization near $580 million, assuming standard over-allotment structures and pre-IPO share counts disclosed in the S-1. Proceeds flow toward retail distribution expansion, new product lines in the functional wellness category, and working capital for a business that has historically burned cash while building brand presence in Whole Foods, Target, and regional grocers.

This matters because consumer CPG exits have been frozen since late 2022. Suja Life's ability to clear the IPO window signals that allocators are willing to pay for revenue growth in health-focused consumables, even without EBITDA breakeven. The company reported $127 million in trailing twelve-month revenue through its most recent disclosed period, up 34% year-over-year, but operating margins remain negative. The willingness to price at midpoint suggests the book was covered without forcing a discount, which is rare for sub-scale food and beverage issuers. Comparable public peers—Vita Coco, Olipop's pending process, and even legacy plays like Hain Celestial—trade between 1.8x and 3.2x forward revenue. Suja's implied multiple sits near 4.6x, pricing in the growth trajectory but leaving little room for margin disappointment.

Operators should track Suja Life's first quarterly earnings release in roughly 90 days, where management will disclose whether the capital raise accelerates velocity per door or simply funds existing burn. Retail data from Circana and SPINS will show if distribution gains translate to household penetration or if the brand remains a niche player. The over-allotment option, typically exercised within 30 days of pricing, will add another $28 million if underwriters take the full greenshoe. Any secondary lockup expirations occur at the standard 180-day mark, landing in mid-Q2 2025, when early investors and employees gain liquidity.

The underwriting syndicate was led by a mid-tier bank, not a bulge bracket, which tells you this was a marketed deal that required work to fill. The stock will trade on momentum and comps, not fundamentals, until at least two quarters of public reporting build a model.